TNGX · available-data snapshot
Tango Therapeutics, Inc. (TNGX): Available-Data Snapshot
TickerWorth does not publish a DCF fair value for Tango Therapeutics, Inc. (TNGX); the reason is set out below. What its filings and market data do show is below. The snapshot also sets out its trading multiples against 5 peers. Snapshot as of Oct 19, 2026.
Model by Miraaj Patel · generated from public market data · Updated Oct 19, 2026 · How these pages are made
Why is there no fair value for TNGX?
We do not publish a fair value for Tango Therapeutics, Inc.. What we can say from its filings and market data is below.
What is TNGX's TickerWorth Score?
Scores lower than almost every company we compare it with
Compared with Healthcare companies in US
Its strongest point: strong balance sheet. Its weakest: profitability is weak.
- Value · 25 of 100
Cheaper than 25% of Healthcare companies in US
- Price vs worth · 0 of 100
- Quality · 9 of 100
More profitable than 9% of Healthcare companies in US
- Financial health · 70 of 100
Financially stronger than 70% of Healthcare companies in US
- Growth · — of 100
- Momentum · 63 of 100
Outperformed 63% of Healthcare companies in US over the past year
Confidence: Medium confidence · Scored
Get the Undervalued Company of the Week.
- Price
- $22.64
- Market cap
- $3,
817, 338, 624 - 52-week high
- $34.39
- 52-week low
- $6.69
- Currency
- USD
- Exchange
- NasdaqGM
Snapshot of Oct 19, 2026, quote time not published · Prices are delayed.
What we can say
We don't publish a discounted-cash-flow fair value for Tango Therapeutics, Inc. (TNGX) because the free data sources we rely on don't expose the multi-year financials a DCF needs — common for small or thinly-covered listings. Rather than invent numbers, this page shows an honest snapshot of what the public data does support: the current price and size, any relative valuation multiples that exist, a book-value view, and a price-based read. Treat it as a descriptive starting point, not a valuation and not investment advice.
Read the full reasoning
On the numbers we do have, TNGX trades at a recent price of $22.64, a market capitalisation of about $3,817,338,624, sitting 58% of the way up its 52-week range ($6.69–$34.39), on the NasdaqGM.
The standard alternative to a DCF is relative valuation — comparing TNGX's trading multiples against a sector benchmark. Here that gives P/B of 3.7× (cheaper than the peer median of 7.9×); P/S of 70.9× (richer than the peer median of 6.2×). A cheaper multiple than peers can flag a discount or a market that expects weaker growth; it is a comparison, not a recommendation.
The asset, or book-value, lens is the classic tool for asset-heavy businesses and financials. TNGX shows a price-to-book (P/B) of 3.72 and book value of $6.08 per share. Price-to-book compares the market price to the accounting net-asset value per share; below 1.0 can mean a discount to net assets or that the market is pricing in trouble — descriptive either way, never a buy signal on its own.
Finally, a price-based read — explicitly not a valuation. TNGX is in a mixed trend, trading -34.2% from its 52-week high. Over the past year the stock is +140.9%. Moving-average trend and 52-week position describe where the stock has traded; they say nothing about what it is worth.
TNGX vs peers
Sector benchmark (bellwethers, not direct competitors).
| Multiple | TNGX | Peer median | Read |
|---|---|---|---|
| P/B | 3.7× | 7.9× | cheaper than |
| P/S | 70.9× | 6.2× | richer than |
What does Tango Therapeutics, Inc. do?
What does it do?
Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need. The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors, including TNG462, which is in Phase 1/2 clinical trial for treating pancreatic and lung cancer; and TNG456, a brain-penetrant PRMT5 inhibitor for the treatment of glioblastoma. It operates in the Biotechnology industry (Healthcare sector), headquartered in United States. The company employs roughly 137 people.
How does it make money?
The business turns $54M in annual revenue into profit. Out of every $100 of sales, about $0 is left as operating profit (operating margin of -253.4%), after a -148% gross margin on the products/services it sells. After all costs, taxes and interest, -229.9% of revenue becomes bottom-line net profit.
Is it financially healthy?
Financially it looks mixed: carries heavy debt (3.1× equity), comfortably covers its short-term bills (50.8× current ratio), and is currently lossmaking.
TNGX insider trading
We have no recent SEC Form 4 insider filings on file for Tango Therapeutics, Inc.. Form 4 covers US-listed companies only.
Companies we do put a number on
Not investment advice. TickerWorth Score is a model output.
A descriptive, available-data snapshot and relative comparison — NOT a DCF, NOT a price target, and NOT investment advice. TickerWorth is not a licensed investment adviser, and these figures are estimates from public market data that can be wrong, stale or incomplete.